Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: The multicenter CARDIAC study

European Journal of Clinical Pharmacology

Volumn 62, Issue 1, 2006, Pages 45-49

  Lenzen, Henrike ^a   Tsikas, Dimitrios ^a   Böger, Rainer H ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Asymmetric dimethylarginine; Cardiovascular risk factor; Nitric oxide

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; TRIACYLGLYCEROL; AMINO ACID; CHOLESTEROL;

ATHEROSCLEROSIS; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; AMINO ACID BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; RISK FACTOR;

EID: 33344456736     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0014-x     Document Type: Conference Paper

References (47)

1. Harrison DG (1997) Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100:2153-2157
2. Ross R (1999) Atherosclerosis is an inflammatory disease. Am Heart J 138:S419-S420
3. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P (1995) The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332:488-493
4. Celermajer DS (1997) Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 30:325-333
5. Drexler H (1997) Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis 39:287-324
6. Cooke JP, Tsao PS (1994) Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb 14:653-655
7. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P (1990) Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81:491-497
8. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A (1993) Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 91:29-37
9. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE (1994) Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 24:1468-1474
10. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III (1995) Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 95:1747-1755
11. Lüscher TF, Noll G (1995) The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis 118(Suppl):S81-S90
12. Levine GN, Keaney JF Jr, Vita JA (1995) Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 332:512-521
13. Castelli WP (1984) Epidemiology of coronary heart disease: the Framingham study. Am J Med 76:4-12
14. Lyons D, Roy S, Patel M, Benjamin N, Swift CG (1997) Impaired nitric oxide-mediated vasodilatation and total body nitric oxide production in healthy old age. Clin Sci 93:519-525
15. Pohl U, Holtz J, Busse R, Bassenge E (1986) Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 8:37-44
16. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376
17. Cooke JP, Dzau VJ (1997) Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 96:379-382
18. Böger RH, Bode-Böger SM, Brandes RP, Phivthong-ngam L, Böhme M, Nafe R, Mügge A, Frölich JC (1997) Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 96: 1282-1290
19. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101:948-954
20. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98: 1842-1847
21. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673-2678
22. Schächinger V, Zeiher AM (2000) Atherosclerosis-associated endothelial dysfunction. Z Kardiol 89(Suppl 9):IX/70-4
23. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-575
24. Faraci FM, Brian JE Jr, Heistad DD (1995) Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 269:H1522-H1527
25. Kurose I, Wolf R, Grisham MB, Granger DN (1995) Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules. Am J Physiol 268:H2224-H2231
26. Segarra G, Medina P, Ballester RM, Lluch P, Aldasoro M, Vila JM, Lluch S, Pelligrino DA (1999) Effects of some guanidino compounds on human cerebral arteries. Stroke 30:2206-2210; discussion 2210-2211
27. Gardiner SM, Kemp PA, Bennett T (1993) Regional haemodynamic responses to intravenous and intraarterial endothelin-1 and big endothelin-1 in conscious rats. Br J Pharmacol 110: 1532-1536
28. Naruse K, Shimizu K, Muramatsu M, Toki Y, Miyazaki Y, Okumura K, Hashimoto H, Ito T (1994) Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler Thromb 14: 746-752
29. Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP (1994) L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb 14:1529-1533
30. Cayatte AJ, Palacino JJ, Horten K, Cohen RA (1994) Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 14:53-59
31. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME (1992) Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 90:1168-1172
32. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP (1992) L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 90:1248-1253
33. Böger RH, Bode-Böger SM, Mügge A, Kienke S, Brandes R, Dwenger A, Frölich JC (1995) Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 117:273-284
34. Bode-Böger SM, Böger RH, Kienke S, Böhme M, Phivthongngam L, Tsikas D, Frölich JC (1998) Chronic dietary supplementation with L-arginine inhibits platelet aggregation and thromboxane A2 synthesis in hypercholesterolaemic rabbits in vivo. Cardiovasc Res 37:756-764
35. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99:1141-1146
36. Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich JC, Böger RH (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-2117
37. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:2127-2128
38. Nijveldt RJ, Teerlink T, Van Der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA (2003) Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 22:23-30
39. Mügge A, Hanefeld C, Böger RH, CARDIAC study investigators (2003) Plasma concentration of asymmetric dimethylarginine and the risk of coronary heart disease: rationale and design of the multicenter CARDIAC study. Atherosclerosis 4 (Suppl):29-32
40. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98: 1842-1847
41. Schwedhelm E (2005) Quantification of ADMA: analytical approaches. Vasc Med 10:1-7
42. Martens-Lobenhoffer J, Bode-Böger SM (2005) Measurement of ADMA in human plasma: from liquid chromatography estimation to liquid chromatography-mass spectrometry quantification. Eur J Clin Pharmacol 61(Suppl)
43. Martens-Lobenhoffer J, Bode-Böger SM (2003) Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. J Chromatogr B 798: 231-239
44. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH (2005) LC-tandem MS method for the analysis of asymmetric dimethylarginine (ADMA) in human plasma. Clin Chem 51:1268-1271
45. G-dimethyl-L-arginine, an endogenous NO synthase inhibitor, by gas chromatography-mass spectrometry. J Chromatogr B 809:59-65
46. Tsikas D, Schubert B, Gutzki FM, Sandmann J, Frölich JC (2003) Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri (N-pentafluoropropionyl) derivative. J Chromatogr B 798:87-99
47. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Böger RH (2004) Determination of ADMA using a novel ELISA assay. Clin Chem Lab Med 42:1377-1383